White & Case has entered appearances for Gilead in Staley v. Gilead Sciences, while Arnold & Porter Kaye Scholer is representing Bristol-Myers Squibb; Drinker Biddle Reath represents Johnson & Johnson; and Holland & Knight reps Japan Tobacco.
Staley alleges that Gilead and the other drug companies have inflated the price of HIV medication through collusive licensing agreements, such as by combining Gilead compounds whose patents are expiring with other companies’ more recently patented compounds into fixed-dose combinations. The strategy is “crippling this nation’s ability to stop new HIV infections,” the plaintiffs contend in a May 14 complaint.
Gilead has said that it enters into partnerships with other companies to create life-saving therapies. “Any suggestion that we had improper motives is absolutely false,” the company has said.
Full Content: Law
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI